ImmunoCellular Therapeutics Ltd.
IMUC.WS
IMUC.WS was delisted on the 16th of October, 2018.
2 hedge funds and large institutions have $1K invested in ImmunoCellular Therapeutics Ltd. in 2018 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.
33% less funds holding
Funds holding: 3 → 2 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
97% less capital invested
Capital invested by funds: $31K → $1K (-$30K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$342 |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$46 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$30K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $1K | +$342 | +14,139 | New |
|
|
AFM
2
Anson Funds Management
Dallas,
Texas
| – | -$30K | -117,187 | Closed |
|
|
SM
3
Sabby Management
Miami Beach,
Florida
| – | -$1K | -74,443 | Closed |
|
|
4
UBS Group
Zurich,
Switzerland
| – | +$46 | +1,895 | +1,895% |
|
IMUC.WS Hedge Fund Activity: Q3 2018 in Review
2 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics Ltd. (IMUC.WS) for Q3 2018, worth a combined $1K — down 97% from $31K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of IMUC.WS and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $342. The largest seller was Anson Funds Management, exiting entirely with an estimated $30K sold.
- 2 institutional investors held ImmunoCellular Therapeutics Ltd. (IMUC.WS) as of Q3 2018, down from 3 in Q2 2018.
- Funds reported $1K of ImmunoCellular Therapeutics Ltd. stock for Q3 2018, down 97% quarter-over-quarter.
- 1 fund opened new ImmunoCellular Therapeutics Ltd. positions in Q3 2018 and 2 closed out, a net change of -1 holder.
- The largest ImmunoCellular Therapeutics Ltd. buyer in Q3 2018 was Citadel Advisors, an estimated $342 added.
- The largest ImmunoCellular Therapeutics Ltd. seller in Q3 2018 was Anson Funds Management, an estimated $30K sold.
Based on aggregated 13F filings for Q3 2018.